CCCC
HEALTHCAREC4 Therapeutics Inc
$2.93-0.04 (-1.35%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CCCC Today?
No stock-specific AI insight has been generated for CCCC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.21$3.82
$2.93
Fundamentals
Market Cap$323M
P/E Ratio—
EPS$-1.27
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-2.9%
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding110.2M
CCCC News
20 articles- Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 5, 2026
- Assessing Roche Holding (SWX:ROG) Valuation After New C4 Therapeutics Oncology PartnershipYahoo Finance·Apr 21, 2026
- Roche’s DAC investment; Big Pharma’s lavish CEO bumpsPharmavoice·Apr 17, 2026
- BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Insight, Epidemiology, and Market Forecast Report 2022-2026 & 2026-2036 Featuring Novartis, Genentech, Fore Biotherapeutic, and C4 TherapeuticsYahoo Finance·Apr 13, 2026
- Roche Explores Degrader Antibody Conjugates To Support Oncology PipelineYahoo Finance·Apr 12, 2026
- Roche and C4 Therapeutics to advance degrader-antibody conjugates researchPharmaceutical-technology·Apr 10, 2026
- C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)Yahoo Finance·Apr 9, 2026
- Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Mar 27, 2026
- C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple MyelomaYahoo Finance·Mar 25, 2026
- Analysts See Significant Upside in C4 Therapeutics (CCCC) StockYahoo Finance·Mar 24, 2026
- C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays ConfabMarketbeat·Mar 14, 2026
- C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial DataYahoo Finance·Mar 10, 2026
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 9, 2026
- C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen ConferenceMarketbeat·Mar 7, 2026
- Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great ChoiceYahoo Finance·Mar 6, 2026
- Is BrightSpring Health Services, Inc. (BTSG) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Mar 5, 2026
- C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsYahoo Finance·Feb 26, 2026
- C4 Therapeutics to Participate in Upcoming March ConferencesYahoo Finance·Feb 23, 2026
- C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple MyelomaYahoo Finance·Feb 23, 2026
- Strong Analyst Confidence in C4 Therapeutics (CCCC)’s Cemsidomide Drives 270% Upside PotentialYahoo Finance·Feb 20, 2026
All 20 articles loaded
Price Data
Open$3.00
Previous Close$2.97
Day High$3.01
Day Low$2.90
52 Week High$3.82
52 Week Low$1.21
52-Week Range
$1.21$3.82
$2.93
Fundamentals
Market Cap$323M
P/E Ratio—
EPS$-1.27
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-2.9%
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding110.2M
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—